TITLE

Miracle Cure?

AUTHOR(S)
Pender, Frank
PUB. DATE
September 2005
SOURCE
PN;Sep2005, Vol. 59 Issue 9, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the use of a product called EPIFLO to treat pressure sores from Ogenix Corp. in Cleveland, Ohio. Safety and efficacy of the novel drug; Mechanism of action; Availability of information about the product online.
ACCESSION #
17938853

 

Related Articles

  • Personalized Medicine or Blockbusterology? Burrill, G. Steven // BioPharm International;Apr2002, Vol. 15 Issue 4, p46 

    Focuses on the ability of pharma companies to create diagnostics linked to therapeutics in the U.S. Goal for a personalized approach to drug discovery, development of individualized patient treatments and disease management strategies; Risks in drug discovery; Increase in drug spending and...

  • The Middle East Market. Baggili, Sacha // Pharmaceutical Executive;Nov2003, Vol. 23 Issue 11, p34 

    Presents an overview of the pharmaceutical market and industry in the Middle East/North Africa region. Absence of high-quality specialized therapies; Prospects for long-term investment in drug manufacturing operations; Economic factors that influence the industry; Negative implications of...

  • Building Blockbusters. Parker, Michael G.; Amar, David // Pharmaceutical Executive;Sep2005, Vol. 25 Issue 9, p82 

    Focuses on the discovery of breakthrough medicine that provide significant therapeutic advantage by the pharmaceutical industry in the U.S. Result of the growing resistance of both public and private payers to pay premium prices for medicines that are not superior to those already available;...

  • Personalized Medicine and Pathology. Aspinall, Mara // Archives of Pathology & Laboratory Medicine;Apr2009, Vol. 133 Issue 4, p527 

    The article focuses on the importance of personalized medicine. Personalized medicine offers ways for physicians to predict the outcome of treatment based on observation and not on trial and error basis. It also offers pharmaceutical companies the ability to produce specific types of drugs and...

  • A first: Drug may safety cut mucositis symptoms. Pfeiffer, Naomi // Drug Topics;2/9/2004, Vol. 148 Issue 3, p52 

    Presents a study sponsored by Amgen Inc. on palifermin as drug treatment for mucositis. Response of patients with severe mucositis on palifermin; Number of patients enrolled in the study; Incidence of severe mucositis.

  • Categories driving future drug trend. Walker, Tracey // Managed Healthcare Executive;Feb2008, Vol. 18 Issue 2, p47 

    The article presents the six top categories of therapeutics for 2007-2009 expected to drive future drug develoment trends. Several medical care executives have their schemes in reducing the costs of medicines, through the combination of gathered information from pharmacies and medical benefits...

  • Methods for Library Design and Optimisation. Green, D. V.S.; Pickett, S. D. // Mini Reviews in Medicinal Chemistry;Dec2004, Vol. 4 Issue 10, p1067 

    The introduction of combinatorial chemistry groups into pharmaceutical companies provoked a desire for efficient and effective methods for library design and optimisation. This, in turn, has resulted in a large number of scientific publications, detailing a variety of approaches to the problem....

  • Integration of Virtual Screening into the Drug Discovery Process. Chin, D. N.; Chuaqui, C. E.; Singh, J. // Mini Reviews in Medicinal Chemistry;Dec2004, Vol. 4 Issue 10, p1053 

    Advances in high-throughput virtual screening using docking, predictive ADME methods and their integration with informatics and high-performance computing are reviewed. Docking approaches have led to the identification of novel active compounds. Predictive ADME methods have improved on selective...

  • Achieving Global Consensus Through the International Conference on Harmonization. Kaufman, Zena G.; Beno, Diane // BioPharm International;Sep2006 Supplement, Vol. 19, p24 

    The article discusses the quality guidances developed by the International Conference on Harmonization (ICH) in the U.S. The author stated that, as an organization composed of regulatory and industry representatives, ICH aimed to apply good scientific principles to pharmaceutical regulations....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics